Markets:

Overview

News

Currencies

International

Treasuries

Milestone Pharmaceuticals Inc. - Common Shares (NQ:MIST)

1.360 -0.340 (-20.00%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Milestone Pharmaceuticals Inc. - Common Shares

< Previous 1 2 3 Next >

What's going on in today's session ↗

Today 13:30 EDT

Via Chartmill

Milestone Pharmaceuticals (NASDAQ:MIST) Reports First Revenue with Q4 2025 Earnings, Beats Estimates ↗

Today 8:20 EDT

Via Chartmill

Topics Earnings

Synergy CHC Corp. (NASDAQ: SNYR) Expands FOCUSfactor® Beverage Platform Further Building Shareholder Value – IMG, YCBD, SURG, URG Inside

December 15, 2025

Via AB Newswire

MIST Stock Soars Pre-Market After FDA Approves First Commercial Product – Retail Remains Bullish, Dismisses ‘Sell The News’ Concerns ↗

December 15, 2025

Milestone stated in its announcement that the approval of Cardamyst opens up an addressable market of more than two million Americans who suffer from PSVT.

Via Stocktwits

Milestone Pharmaceuticals: Q4 Earnings Insights ↗

March 21, 2024

Via Benzinga

Monday's pre-market session: top gainers and losers ↗

December 15, 2025

As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Via Chartmill

Let's take a look at the stocks that are in motion in today's session. ↗

December 12, 2025

Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Milestone Pharmaceuticals (NASDAQ:MIST) Posts Narrower-Than-Expected Q3 Loss as Key FDA Decision Looms ↗

November 12, 2025

Milestone Pharmaceuticals beat Q3 earnings estimates, with a narrower loss. The stock rose as investors await the December 2025 FDA decision for its lead drug, CARDAMYST™.

Via Chartmill

Let's take a look at the stocks that are in motion in today's session. ↗

July 11, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge ↗

July 11, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

July 11, 2025

Via Benzinga

Which stocks are moving on Friday? ↗

July 11, 2025

Stay up-to-date with the latest market trends in the middle of the day on Friday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

Why Is Milestone Pharmaceuticals Stock Plunging On Friday? ↗

July 11, 2025

FDA accepts Milestone's response on Cardamyst nasal spray, sets new PDUFA date; company raises $52.5 million to support potential PSVT treatment launch.

Via Benzinga

Dow Dips Over 200 Points; Levi Strauss Posts Upbeat Earnings ↗

July 11, 2025

Via Benzinga

Topics Stocks

There are notable gap-ups and gap-downs in today's session. ↗

July 11, 2025

Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Via Chartmill

Wondering what's happening in today's pre-market session? ↗

July 11, 2025

The US market session of Friday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Via Chartmill

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

July 11, 2025

Via Benzinga

Top movers analysis one hour before the close of the markets on 2025-03-28: top gainers and losers in today's session. ↗

March 28, 2025

Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Top movers in Friday's session ↗

March 28, 2025

Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements.

Via Chartmill

Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Retail’s Positive ↗

March 28, 2025

The FDA said an inspection is required at a facility where the company performed release testing for the product to ensure it complies with Current Good Manufacturing Practices.

Via Stocktwits

12 Health Care Stocks Moving In Friday's Intraday Session ↗

March 28, 2025

Via Benzinga

Traders are paying attention to the gapping stocks in Friday's session. ↗

March 28, 2025

Let's have a look at what is happening on the US markets on Friday. Below you can find the gap up and gap down stocks in today's session.

Via Chartmill

Dow Tumbles Over 500 Points; Abacus Global Management Shares Spike Higher ↗

March 28, 2025

Via Benzinga

Topics Stocks

Top movers in Friday's pre-market session ↗

March 28, 2025

The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Via Chartmill

Why Is Milestone Pharmaceuticals Stock Plunging Today? ↗

March 28, 2025

Milestone Pharmaceuticals' stock drops over 61% after receiving a Complete Response Letter from the FDA for its CARDAMYST NDA.

Via Benzinga

Nasdaq Down 100 Points; Federal Reserve's Favorite Inflation Gauge Increases More Than Expected ↗

March 28, 2025

Via Benzinga

Topics Economy

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

March 28, 2025

Via Benzinga

MIST Stock Earnings: Milestone Pharmaceuticals Beats EPS for Q2 2024 ↗

August 09, 2024

MIST stock results show that Milestone Pharmaceuticals beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

MIST Stock Earnings: Milestone Pharmaceuticals Beats EPS for Q1 2024 ↗

May 13, 2024

MIST stock results show that Milestone Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

MIST Stock Earnings: Milestone Pharmaceuticals Misses EPS for Q4 2023 ↗

March 21, 2024

MIST stock results show that Milestone Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.